Expertise in
17
conditions

Dr. Reinhold M. Munker

Hematology
Office
750 Rose St, 
Lexington, KY 
Expertise in
17
conditions
Office
750 Rose St, 
Lexington, KY 

Overview

Reinhold Munker is a Hematologist practicing medicine in Lexington, Kentucky.

Dr. Munker is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 68 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in KY

Hospital Affiliations

University Of Kentucky Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Office
750 Rose St, Lexington, KY 40536

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
View 4 Less Clinical Trials

68 Total Publications

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report.
Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report.
Journal: Frontiers in oncology
Published: May 19, 2026
Similar Doctors
Expertise in
46
conditions
Dr. Firas Badin
Hematology | Oncology
Expertise in
46
conditions
Dr. Firas Badin
Hematology | Oncology
Referral may be required

Baptist Health Medical Group-Palliative Medicine

1700 Nicholasville Rd Ste 1100, 
Lexington, KY 
 (2.3 miles away)
859-276-0414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Firas Badin is a Hematologist and an Oncologist practicing medicine in Lexington, Kentucky. Dr. Badin is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Badin is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Health Service

830 Rose St, 
Lexington, KY 
 (0.1 miles away)
859-323-0303
Languages Spoken:
English
See accepted insurances

Gregory Monohan is a Hematologist practicing medicine in Lexington, Kentucky. Dr. Monohan is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Amy Schell
Hematology | Oncology
Expertise in
29
conditions
Dr. Amy Schell
Hematology | Oncology
Referral may be required

Baptist Health Medical Group-Palliative Medicine

1700 Nicholasville Rd Ste 1100, 
Lexington, KY 
 (2.3 miles away)
859-276-0414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Schell is a Hematologist and an Oncologist practicing medicine in Lexington, Kentucky. Dr. Schell is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Breast Cancer. Dr. Schell is currently accepting new patients.

Frequently Asked Questions about Dr. Reinhold M. Munker

How do I make an appointment with Dr. Reinhold M. Munker?

You can book an appointment with Dr. Reinhold M. Munker by calling their office at 859-257-4488. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Reinhold M. Munker a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Reinhold M. Munker is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Reinhold M. Munker specialize in?

While Dr. Reinhold M. Munker is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, and Chronic Graft Versus Host Disease (cGvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Reinhold M. Munker participate in research or clinical trials?

Yes. Dr. Reinhold M. Munker has published 68 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Reinhold M. Munker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Reinhold M. Munker accept my insurance?

Dr. Reinhold M. Munker accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 859-257-4488 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Munker's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 56 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile